All In Biotech

Drug Trial Radar · NCT07827599

A Study to Confirm Efficacy of a Single Dose of Baloxavir Marboxil in the Post-exposure Prophylaxis (PEP) of Influenza Virus Infection in Chinese Participants

A Phase III, Randomized, Double-blinded, Placebo-controlled Study to Confirm Efficacy of a Single Dose of Baloxavir Marboxil in the Post-exposure Prophylaxis of Influenza Virus Infection in Chinese Participants

Last checked: Nov 20, 2026Latest source record: Nov 17, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 325 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

325

Planned (sponsor's estimate)

Start

Oct 16, 2026

Primary completion

Apr 30, 2027

Study completion Apr 30, 2027

Sponsor

Lead sponsor
Hoffmann-La RocheRoche (Genentech) (RHHBY)
Sponsor type
Industry
First posted
Sep 18, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, care provider, investigator)
Primary purpose
Prevention
FDA-regulated drug
No
Who can join
All sexes, from 5 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The main purpose of the study is to evaluate the efficacy of a single dose of baloxavir marboxil compared with placebo in the PEP of influenza virus infection with respect to symptomatic, laboratory-confirmed influenza in participants who are household contacts (HHCs) of participants with influenza (index participants).

Conditions

  • Influenza, Human
  • Respiratory Tract Infections
  • Post-exposure Prophylaxis

Interventions

  • Baloxavir marboxilDrug

    Baloxavir marboxil will be administered to the HHCs as per the schedule specified in the protocol.

  • PlaceboDrug

    Baloxavir marboxil matching placebo will be administered to the HHCs as per the schedule specified in the protocol.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of Participants who are Infected With Influenza Virus (Reverse Transcription - Polymerase Chain Reaction [RT-PCR] Positive), and Present With Fever and at Least one Respiratory SymptomTime frame: From Day 1 up to Day 10

Locations

20 sites in 1 country. Site status is shown where the registry gives one.

  • The First People's Hospital of Changde

    Changde, China · Recruiting

  • Peoples Hospital of Hunan Province

    Changsha, China · Recruiting

  • Huizhou Central People's Hospital

    Huizhou, China · Recruiting

  • Jiujiang No.1 People's Hospital

    Jiujiang, China · Recruiting

  • Hebei Petro China Central Hospital

    Langfang, China · Recruiting

  • Liuzhou People's Hospital

    Liuzhou, China · Recruiting

  • Luoyang Central Hospital

    Luoyang, China · Recruiting

  • Ningbo No.2 Hospital

    Ningbo, China · Recruiting

  • Ningbo Women and Children's Hospital

    Ningbo, China · Recruiting

  • Pingxiang People's Hospital

    Pingxiang, China · Recruiting

  • Sanmenxia Central Hospital

    Sanmenxia, China · Recruiting

  • The Third People's Hospital of Hainan Province

    Sanya, China · Recruiting

  • Huashan Hospital Affiliated to Fudan University

    Shanghai, China · Recruiting

  • The First Affiliated Hospital, Shaoyang University

    Shaoyang, China · Recruiting

  • Shijiazhuang People's Hospital

    Shijiazhuang, China · Recruiting

  • Weifang No.2 People's Hospital

    Weifang, China · Recruiting

  • Xiamen Maternal and Child Health Hospital

    Xiamen, China · Recruiting

  • Zhujiang Hospital, Southern Medical University

    Guangzhou, Guangdong, China · Recruiting

  • Affiliated Hospital of Zunyi Medical University

    Zunyi, Guizhou, China · Recruiting

  • Mianyang Central Hospital

    Mianyang, Sichuan, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.